insight hs kol call affirm thesi inflarx
week host kol call hidraden suppurativa hs inflarx
ifrx develop target mab call kol two top hs
field dr iltefat hamzavi henri ford health system detroit dr chri say
univers north carolina in-depth biographi kol end note
feedback call consist prior analysi moderate-to-sever hs market
vastli underestim potenti ration target develop
hs initi data highli compel clear need treatment
use ahead follow abbvi nyse humira drug approv
diseas lack durabl activ patient replay call found
transcript day reach us copi
could million peopl us moderate-to-sever hs true
preval number model underestim kol note
belief us preval data literatur good hs one common estim
moderate-to-sever patient us conserv use
model partial base humira grant orphan-design diseas howev
dr hamzavi note one hs commun believ number accur base
work dr hamzavi group hs commun conserv estim preval
hs us million peopl moderate-to-sever group million
size dr say agre note probabl million hs patient us
moderate-to-sever group around million size possibl bigger
part reason drastic underestim preval diseas often
misdiagnos code accur lead patient hidden medic
system wrong code support fact mean time diagnosi around
year patient howev physician note due greater awar market
humira number identifi patient rapidli grow
year left
short interest float
hs extrem debilit kol describ hs terribl debilit emot
deleteri skin diseas one worst dermatolog diseas patient experi
term impact qualiti life hs blow someth like psoriasi water
dermatolog life qualiti index dlqi consist wors despit fact
dlqi dont take account drainag odor come hs present
skin diseas
 result phase iib trial hs
 announc new indic
analyst certif disclosur pleas see page
signific room improv humira hs base pivot studi humira half patient experi hiscr respons
week approv endpoint half respond remain respons week dr hamzavi note experi
patient dramat respons humira rest mild-to-no respons dr say experi
well enough humira want stay treatment prolong period time see improv enough
worth continu treatment around experi benefit humira upcom data readout even
good humira physician would happi given major patient sub-optimal respons humira need
second-lin treatment also note depend patient insur abil afford humira prolong period time
issu sinc given double-dos sometim hs howev appear much issu dr hamzavi
clinic dr say
superior humira would good reason use first-lin treatment patient would prefer therapi
highest chanc control diseas subcutan superior dr hamzavi think could use treat
moderate-to-sever patient prior convers dr say note believ sq could use moderate-to-sever
patient led increas respons rate compar humira caveat substanti long-term safeti data
humira collect data simpli take time dont think dramat sway physician patient choic
also note test patient advers event similar placebo treat patient
impress data date hs data expect placebo-control random phase iib trial
moderate-sever hs studi support open-label phase iia result use patient hurley stage diseas sever
form either fail respond inelig humira show strong activ difficult treat popul
patient achiev clinic respons therapi week measur hiscr respond end addit
month observ period treatment stop admit data small open-label studi hiscr rate durabl
respons exceed result trial popul addit key endpoint qualiti life improv also encourag
dr hamzavi dr say note preliminari data impress acknowledg look better data
point differenti hiscr rate especi given sever diseas patient durat respons
come kol note patient come humira typic flare within month
consid best target hs date ask humira lack-lust activ hs dr hamzavi note
stabl activ phase hs activ phase patient actual releas tnf- lot patient
inflammatori mediat cytokin involv howev factor releas
time degre stabl phase hs patient signific scar limit mobil activ phase
start limit space inflamm sinu tract caus addit pain summari hs one uniform diseas
biochem profil differ phase diseas
potent inflammatori mediat strong chemoattractant/activ neutrophil also influenc product
proinflammatori cytokin contribut immun respons hs support data show significantli greater concentr
plasma hs patient compar healthi control well ex vivo result show main regul
tnf- product patient target potent reduc number activ mani aforement effector cell
cytokin downstream mean instead target singl cytokin immun cell type involv hs pathogenesi
regul multitud dr hamzavi believ compel target far hs support current clinic
data note neutrophil heavili involv hs import remov also look pathway
common pathway activ hs help regul key cytokin involv diseas
christoph say md assist professor dermatolog unc health special gener dermatolog dermatolog surgeri
laser servic especi interest treat adult patient hidraden suppurativa publish extens subject dr
say also activ involv speak medic confer present new research treatment hs board certifi dermatolog
receiv md univers north carolina chapel hill
dr iltefat hamzavi md practic dermatologist special focu pigmentari disord hidraden suppurativa dr hamzavi receiv
medic degre univers michigan medic school dr hamzavi activ clinic research investig caus treatment
vitiligo hidraden suppurativa photomedicin condit addit privat practic dr hamzavi also serv senior staff
physician henri ford depart dermatolog teach medic student wayn state univers co-author
peer review paper cite time highli respect journal also volunt time varieti non-
profit educ civic engag bring attent debilit skin diseas serv found co-chair global vitiligo
foundat presid hidraden suppurativa foundat
twelve-month price target base dcf valuat model assum discount rate termin growth rate million
fulli dilut share pro-forma also incorpor premium due potenti expand sever addit indic
potenti upsid model includ better expect clinic result could requir us boost peak penetr probabl
success relev indic increas target popul moderate-sever patient expans addit indic
potenti success earlier anticip regulatori approv sale surpass expect patent extens
risk price target includ wors expect clinic result unforeseen competit emerg initi
target indic chang regulatori environ market downturn potenti dilut financ
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
